Showing results (341-350 of 365) with videos related to
Sort By:
Pageof 37
Lancet (London, England)|December 14, 2020
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trialsIlse De Coster, Isabel Leroux-Roels, Ananda S Bandyopadhyay, et al.Pediatrics|July 17, 2016
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical TrialsEdson D Moreira, Stan L Block, Daron Ferris, et al.Immunogenetics|December 3, 2017
Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinityPieter Meysman, Nicolas De Neuter, Esther Bartholomeus, et al.Biorxiv : the Preprint Server for Biology|March 30, 2023
Integrated Drivers of Basal and Acute Immunity in Diverse Human PopulationsAisha Souquette, E Kaitlynn Allen, Christine M Oshansky, et al.Science Advances|May 16, 2025
Celluloepidemiology-A paradigm for quantifying infectious disease dynamics on a population levelMy K Ha, Anna Postovskaya, Maria Kuznetsova, et al.Lancet (London, England)|June 9, 2019
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 studyPierre Van Damme, Ilse De Coster, Ananda S Bandyopadhyay, et al.JAMA Network Open|October 12, 2021
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical TrialTimo Vesikari, Adam Finn, Pierre van Damme, et al.Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.Journal of Translational Medicine|August 25, 2019
Diagnosing enterovirus meningitis via blood transcriptomics: an alternative for lumbar puncture?Esther Bartholomeus, Nicolas De Neuter, Annelies Lemay, et al.Vaccine|March 7, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 studyElmar A Joura, Angels Ulied, Corinne Vandermeulen, et al.Pageof 37